Cargando…

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2

[Image: see text] Inhibition of the sodium–glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in large between-patient variability in clinical response. To better understand this variability, the positron emission tomography (PET) tracer [(18)F]canagliflozin was dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Hoek, Sjoukje, Antunes, Inês F., Attia, Khaled A., Jacquet, Olivier, Heeres, Andre, Bulthuis, Marian, Zijlma, Rolf, Boersma, Hendrikus H., van Goor, Harry, Visser, Ton J., Heerspink, Hiddo J. L., Elsinga, Philip H., Stevens, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631709/ https://www.ncbi.nlm.nih.gov/pubmed/34748702 http://dx.doi.org/10.1021/acs.jmedchem.1c01269

Ejemplares similares

Improved GMP-compliant multi-dose production and quality control of 6-[(18)F]fluoro-L-DOPA
por: Luurtsema, G., et al.
Publicado: (2016)

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ (11)C]Telmisartan
por: van der Hoek, Sjoukje, et al.
Publicado: (2022)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

GMP-Compliant Radiosynthesis of [(18)F]GP1, a Novel PET Tracer for the Detection of Thrombi
por: Hugenberg, Verena, et al.
Publicado: (2021)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Pharmacokinetic Modeling of [(11)C]GSK-189254, PET Tracer Targeting H(3) Receptors, in Rat Brain
por: Ghazanfari, Nafiseh, et al.
Publicado: (2022)

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [(68)Ga]Ga-ABY-025 tracer
por: Jussing, Emma, et al.
Publicado: (2023)

Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
por: van der Hoek, Sjoukje, et al.
Publicado: (2022)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
por: Cardinale, Jens, et al.
Publicado: (2017)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

New sensitive method for HEPES quantification in (68)Ga-radiopharmaceuticals
por: Antunes, I. F., et al.
Publicado: (2020)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Standardized GMP-compliant scalable production of human pancreas organoids
por: Dossena, Marta, et al.
Publicado: (2020)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Cell-based medicinal products and the development of GMP-compliant processes and manufacturing
por: Romagnoli, Luca, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC
por: Fekete, Natalie, et al.
Publicado: (2012)

Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide
por: Tshibangu, Térence, et al.
Publicado: (2020)

Creation of GMP-Compliant iPSCs From Banked Umbilical Cord Blood
por: Tian, Pei, et al.
Publicado: (2022)

Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [(18)F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer
por: Katzschmann, Ines, et al.
Publicado: (2021)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Canagliflozin, an Inhibitor of the Na(+)-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
por: Shim, Bosung, et al.
Publicado: (2023)

Fully Automated GMP-Compliant Synthesis of [(18)F]FE-PE2I
por: Bratteby, Klas, et al.
Publicado: (2021)

Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets
por: Fonseca, Alexandra I., et al.
Publicado: (2022)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation
por: Radisch, Sabine, et al.
Publicado: (2022)

Optimised GMP-compliant production of [(18)F]DPA-714 on the Trasis AllinOne module
por: Cybulska, Klaudia A., et al.
Publicado: (2021)

GMP-compliant (68)Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use
por: Vis, Roeland, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ta2vjsfuigvq63dlska1c13k7a